Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
IpiNovyx Bio logo — We are a drug platform focused on treating autoimmune and in...

IpiNovyx Bio

We are a drug platform focused on treating autoimmune and inflammatory diseases.

Founded 2021 United States United States 6 employees Seed Total: $10.00M Biopharma, Biotechnology +1

General Information

Company Name IpiNovyx Bio
Founded Year 2021
Location United States United States
Employees 6
Industries Biopharma, Biotechnology, Health Care
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with IpiNovyx Bio. To contact IpiNovyx Bio, visit ipinovyxbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does IpiNovyx Bio compare?

A PDF of IpiNovyx Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting IpiNovyx Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About IpiNovyx Bio

IpiNovyx Bio, founded in 2021, is a promising startup in the Biopharma and Biotechnology sectors, with a specific focus on Health Care. The company is headquartered in the United States.

Embodying the slogan, "We are a drug platform focused on treating autoimmune and inflammatory diseases," IpiNovyx Bio is developing a series of highly selective, ultra-potent, small molecule therapeutics aimed at transforming the treatment of autoimmune and inflammatory disorders. This disruptive technology holds significant potential to redefine therapeutic approaches, offering new hope for patients.

The startup attracted a noteworthy $10.00M in seed investment on 01 October 2021, with backing from reputable investors such as Viva BioInnovator, Alexandria Venture Investments, Lilly Ventures, Opaleye Management, and Orange Grove Bio. This backing underscores the confidence in IpiNovyx Bio's innovative capabilities and its potential impact on the biopharmaceutical landscape.

Business keywords: Autoimmune Diseases, Inflammatory Diseases, Biopharmaceuticals, Small Molecule Therapeutics, Immunoproteasome Modulation, Immunoproteasome Inhibitors, Selective Drug Targeting, Immune Cell Modulation, Selective Inhibition, Therapeutic Development, Precision Medicine, Drug Discovery, Clinical Validation, Biotechnology Innovations, Healthcare Advancement

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed $10.00M 5
Viva BioInnovator Alexandria Venture Investments Lilly Ventures
Viva BioInnovator, Alexandria Venture Investments +3
01 Oct 2021
Spinout Undisclosed 2
Cornell Capital
Cornell Capital, Cornell University
01 Jan 2021

IpiNovyx Bio Alternatives & Competitors

View All Alternatives
IpiNovyx Bio vs
Third Harmonic Bio
Third Harmonic Bio United States

Advancing the next wave of medicine for inflammatory diseases

Series B
8 employees
Biotechnology, Health Care
IpiNovyx Bio vs
Xanthus Pharmaceuticals
Xanthus Pharmaceuticals

Innovative treatments for cancer and autoimmune disorders through pioneering small-molecule therapeu...

Series B
Biopharma, Biotechnology
IpiNovyx Bio vs
CGI Pharmaceuticals, Inc.
CGI Pharmaceuticals, Inc. United States

CGI Pharmaceuticals was a venture-backed kinase drug discovery company. Founded out of Yale Universi...

Series C
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About IpiNovyx Bio

We are a drug platform focused on treating autoimmune and inflammatory diseases.
IpiNovyx Bio was founded in 2021.
IpiNovyx Bio is headquartered in United States.
IpiNovyx Bio operates in Biopharma, Biotechnology and Health Care. Its work centres on Autoimmune Diseases, Inflammatory Diseases, Biopharmaceuticals and Small Molecule Therapeutics.
IpiNovyx Bio has approximately 6 employees.
IpiNovyx Bio has completed 2 funding rounds, raising a total of $10.00M. The latest funding stage is Seed.
Top alternatives and competitors to IpiNovyx Bio include Third Harmonic Bio, Xanthus Pharmaceuticals, CGI Pharmaceuticals, Inc., Anthera Pharmaceuticals, Palatin Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IpiNovyx Bio and Third Harmonic Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for IpiNovyx Bio, https://bouncewatch.com/company/ipinovyx-bio, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes